Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06480240 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by OBI Pharma.

Active
Registry status
Phase 1
Development phase
117
Enrollment target
8
Study locations

NCT06480240: Active Phase 1 study of Advanced Solid Tumor, sponsored by OBI Pharma.

NCT06480240 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by OBI Pharma. The registered enrollment target is 117 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (39% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06480240, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by OBI Pharma.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
117 participants
Enrollment target
8
Study locations

Study Summary

This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) is intended to further characterize the safety and preliminary clinical activity profile of the RP2D of OBI-992 in subjects with advanced solid tumors.

Primary Outcome

To determine the safety and tolerability of OBI-992 when administered to subjects with advanced solid tumors, based on adverse events (AEs), serious adverse events (SAEs) and laboratory abnormalities graded by NCI CTCAE v5.0

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG OBI-992

Study Locations (8)

California

  • California Clinical Trials Medical Group (CCTMG) - Glendale
  • Scripps Green Hospital - La Jolla

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • NEXT Oncology - San Antonio

Michigan

  • Karmanos Cancer Institute - Detroit

Virginia

  • NEXT Virginia - Fairfax

Xindian District

  • Taipei Tzu Chi Hospital - New Taipei City

Zhonghe District

  • Taipei Medical University - Shuang Ho Hospital - New Taipei City

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2024-06-12
Est. Completion 2027-06
Phase Phase 1
OBI Pharma

7 total trials

What the registry record for NCT06480240 still lists

NCT06480240 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (39% lower).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which OBI-992 is the first listed.

NCT06480240 lists 8 locations in 6 states (California, Texas, Michigan).

Frequently Asked Questions

What is clinical trial NCT06480240 about?

NCT06480240 is a clinical study titled "A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors". This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) i...

What is the current status of trial NCT06480240?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2024-06-12. Estimated completion is 2027-06.

What conditions does trial NCT06480240 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06480240?

The interventions under investigation include: OBI-992 (DRUG).

Who is sponsoring clinical trial NCT06480240?

This trial is sponsored by OBI Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06480240 being conducted?

This trial has 8 study locations across California, Michigan, Texas, Virginia, Xindian District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06480240's enrollment target sits among peer trials

117 106th of 189 higher than 84 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03539822 · 117 participants · Phase 1

    Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  • NCT03786692 · 117 participants · Phase 2

    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

  • NCT04479696 · 117 participants · NA

    Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

  • NCT04940585 · 117 participants · NA

    ROSE in Sunset Park

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06480240, the US trial registry maintained by the National Library of Medicine. NCT06480240 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.